![](https://ml.globenewswire.com/media/7f3ae7f0-9da7-487d-bb04-6c116f345054/small/shattuck-logo-dark-h-png.png)
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in ...
– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had not yet been reached – – Observed 43% …